OTC Markets OTCPK - Delayed Quote USD

Kadimastem Ltd (KMSTF)

6.40

0.00

(0.00%)

At close: January 23 at 7:00:00 PM EST

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announces that Kadimastem has issued a notice t

PR Newswire 9 days ago

KMSTF
0.00%
NLSP

NLSPW
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announce the successful completion of the initi

PR Newswire 17 days ago

NLSP

NLSPW

KMSTF
0.00%
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announced today that NLS has file

PR Newswire 26 days ago

KMSTF
0.00%
NLSP

NLSPW
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

PluriCDMO™, the Company’s contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innovative life science companiesHAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech tra

GlobeNewswire 6 months ago

PLUR

KMSTF
0.00%
IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market

IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IMC"), a leading medical cannabis company with operations in Israel and Germany, announces the termination of the preliminary term sheet signed on February 13, 2024 with Kadimastem Ltd a public company traded on the Tel Aviv Stock Exchange under the symbol (TASE:KDST) ("Kadimastem").

CNW Group 7 months ago

IMCC

KMSTF
0.00%
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company

IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that it has entered into a non-binding term sheet dated February 13, 2024, as amended (the "Term Sheet"), and a Loan Agreement (as defined below) with Holding Company (as defined below), with Israel-based Kadimastem Ltd a clinical cell therapy public company traded on the Tel Aviv Stock Exchange under the symbol (TASE: KDST) ("Kad

CNW Group 10 months ago

KMSTF
0.00%
IMCC

Performance Overview

Return	KMSTF	TA-125
YTD	0.00%	+6.89%
1-Year	+885.23%	+37.18%
3-Year	+220.20%	+21.04%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kadimastem Ltd (KMSTF)

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market

IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company

Performance Overview